陳立宗 特聘研究員－研究領域

EXPERTISE

Medical Oncology, Gastroenterology, Experimental therapy and Translational Research

RESEARCH INTERESTS

As a qualified gastroenterologist and oncologist, Dr. Chen focuses on the development of innovative strategies for treating prevalent gastrointestinal tract (including, hepatobiliary and pancreas) cancers in Taiwan, through conducting clinical trials and trial-related translational research.

RESEARCH ACTIVITIES & ACCOMPLISHMENT

Through conducting innovative clinical trials, Dr. Chen have participated in organizing several distinguished research teams to perform clinical and translational research, notably, antibiotics as first-line therapy for Helicobacter pylori-positive, early-stage high-grade transformed mucosa-associated lymphoid tissue lymphoma of the stomach; thalidomide as salvage therapy for far advanced hepatocellular carcinoma; adjuvant interferon alpha-2b for hepatitis virus-related hepatocellular carcinoma with curative resection; docetaxel-containing triplet chemotherapy for advanced gastric cancers, and gemcitabine-based doublet and triplet chemotherapy for advanced pancreatic cancer.

CLINICAL STUDIES
  • Phase II trial of medroxyprogesterone acetate plus weekly 24-hour infusion of high-dose 5-FU/leucovorin in advanced gastric cancer (Principal investigator, NHRI CCRW, 1995/08)
  • Phase II trial of medroxyprogesterone acetate plus weekly 24-hour infusion of high-dose 5-FU/leucovorin in metastatic gastric cancer with prior chemotherapy (Principal investigator, NHRI CCRW,1995/08)
  • Eradication of Helicobacter pylori in the management of stage IE and IIE-1 primary low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type of the stomach (Principal investigator, TCOG, 1996/03 ~1999/10)
  • Phase II trial of 24-hour infusion of 5-FU/LV following gemcitabine in advanced pancreatic adenocarcinoma. (Principal investigator, CCRC, 1997/6 ~2000/9)
  • Phase II trial of liposomal-adriamycin (Doxil) in inoperable hepatocellular carcinoma (Principal investigator, CCRC, 1997/06 ~).
  • Phase III randomized trial comparing adjuvant recombinant interferon-a versus conservative treatment in postoperative hepatocellular carcinoma (Principal investigator , TCOG, 1997/10 ~ 2003/04)
  • Dose finding study of weekly docetaxel followed by 24-hour infusion of high-dose 5-FU/leucovorin and cisplatin in the management of advanced gastric cancer (Principal investigator, NHRI CCRW, 1998/08 ~ 1999/12)
  • Multi-centre trial of 5-FU/leucovorin/oxaliplatin in the treatment of 5-FU/ leucovorin resistant colorectal cancer (Co-investigator, 1999/09 ~2000/05)
  • Phase II study of biweekly Oxaliplatin plus 46-hour infusion of fluorouracil and leucovorin as second-line therapy in HDFL-failed advanced gastric cancer. (Principal investigator, NHRI CCRC, 1999/04 ~ 2000/10)
  • Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma (Principal investigator, NHRI CCRC, 2000/01 ~ 2000/08)
  • A Phase II study of oxaliplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the first-line treatment of inoperable, locally advanced or recurrent/metastatic gastric cancer (Co-investigator, 2000/10 ~2002/08)
  • Phase I/II study of biweekly gemcitabine, oxaliplatin and 46-hour infusion of fluorouracil and leucovorin in advanced pancreatic cancer. (Principal investigator, NHRI CCRC, 2002/01 ~ 2005/06)
  • Pilot study of biweekly oxaliplatin plus 46-hour infusion of fluorouracil and leucovorin in metastatic/unresectable biliary tree cancer. (Principal investigator, NHRI CCRC, 2001/05 ~ 2004/06)
  • Placebo-controlled, randomized phase III trial of oral thalidomide in advanced HCC patients with poor liver reserve. (Principal investigator, TCOG, 2003/02 ~ ongoing)
  • Phase II study of weekly paclitaxel plus oral UFT/leucovorin in advanced gastric cancer. (Co-PI, Multicentre study, 2003/ ~ 2004/12)
  • Randomized phase II study of pegylated-arginine deiminase (ADI-PEG 20) in advanced hepatocellular carcinoma. (PI, Industry sponsored, multicentre study, 2004/02 ~ 2004/10)
  • Phase II study of neoadjuvant GOFL followed by gemcitabine-based concurrent chemoradiotherapy in locally advanced pancreatic cancer. (PI, PI-initiated, TCOG study, 2004/06 ~ 2008/07)
  • Phase II study of biweekly oxaliplatin plus 46-hour infusion of fluorouracil and leucovorin in metastatic/unresectable biliary tree cancer. (PI, PI-initiated, multicentre study, 2004/06 ~ )
  • Phase I study of ALIMTA plus cisplatin in advanced gastric cancer (Co-PI, Industry-sponsored, multicentre study, 2004/ ~ )
  • Phase I and pharmacokinetic study of liposomal-irinotecan in refractory solid tumors. (Co-PI, Industry-sponsored, multicentre study, 2005/ 02 ~ 2006/04)
  • Phase I and pharmacokinetic study of liposomal-irinotecan plus weekly HDFL in refractory solid tumors. (PI, Industry-sponsored, multicentre study, 2006/09 ~ 2008/04)
  • Randomized, phase I and pharmacokinetic study of RAD001, a m-TOR inhibitor, in advanced hepatocellular carcinoma. (PI, PI-initiated, NHRI Cooperative Ward Study, 2007/03 ~ 2009/02)
  • Randomized, phase III trial of adjuvant of therapeutic lamivudine versus prophylactic adefovir in post-operative low-risk HBV-related HCC (PI, PI-initiated, TCOG T1206 Study, 2007/03 ~ 2010/08, early terminated)
  • Randomized Phase I/II of Rapamycin Analog, RAD001, in Advanced Hepatocellular Carcinoma – with a Pharmacokinetic Study of RAD001 (PI, PI-initiated, 2007/12~2014/05)
  • Randomized, phase II trial of docetaxel versus irinotecan versus PEP02 as second-line treatment in advanced gastric cancer (Co-PI, industry-sponsored, international study, 2008/04 ~ 2009/08)
  • Phase II Study of PHY906 plus Capecitabine in Patients with Advanced or Metastatic Hepatocellular Carcinoma (PI, Industry-sponsored, 2008/07~2012/09)
  • Phase I and PK study of sorafenib plus RAD001 in advanced HCC (Co-PI, Industry-sponsored, international study, 2009/02 ~)
  • A Phase II Study of PEP02 as a second line therapy for patients with metastatic pancreatic cancer (Global Chair, Industry-sponsored, 2009/02~2010/09)
  • Phase I and Pharmacokinetic Study of Biweekly PEP02 (Liposome Irinotecan) in Patients with metastatic colorectal cancer refractory to first-line oxaliplatin-based chemotherapy (Co-investigator, Investigator-initiated, 2009/03~2013/05)
  • Randomized, phase III trial of adjuvant of gemcitabine +/- CCRT in pancreatic cancer after curative intent surgery (Chair, PI-initiated, TCOG T3207 Study, 2009/02~ 2015/05, early terminated)
  • EXPAND (Erbitux in combination with Xeloda and Cisplatin in advanced esophago-gastric cancer). Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction. (Co-PI, Industry-sponsored, 2009/05~2012/08)
  • An Open-Label Phase I Dose-Escalation Study of Sorafenib plus S-1 in Advanced Solid Tumors (PI, PI-initiated, 2009/08~2015/06)
  • A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after failure of sorafenib treatment– The EVOLVE-1 Study (Global co-chair, Industry-sponsored, 2010/09~2012/03)
  • A Randomized phase II study of gemcitabine plus oxaliplatin (GEMOX) with or without cetuximab in locally advanced and metastatic biliary tract cancer (ABTC) (Chair, PI-initiated, 2010/10~2014/09)
  • A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic Cancer (Co-PI, Industry-sponsored, 2011/01~2013/12)
  • A phase I dose escalation study of SCB01A in subjects with advanced solid tumors who have failed standard therapy (PI, Industry-sponsored, 2011/01~2015/09)
  • Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin andGemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma (Chair, PI-initiated, 2011/04~2015/08)
  • A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients with Advanced GIST Failed to or Intolerance of Imatinib and Sunitinib Therapy (PI, PI-initiated, 2011/05~2015/05)
  • A phase I dose escalation trial of weekly intravenous administrations of BI 836845 in patients with advanced solid cancers with repeated administrations in patients showing clinical benefit (PI, Industry-sponsored, 2011/09~)
  • Using genetic polymorphisms of drug metabolism and immunohistochemical stain to predict the efficacy and toxicity in patients with gastric adenocarcinoma – A phase II study (Co-investigator, PI-initiated, 2012/03~)
  • A randomized, open-label phase 3 study of MM-398 versus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer (Steering Committee Member, Industry-sponsored, 2012/05~2013/09)
  • Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy (Co-PI, Industry-sponsored, 2013/01~2015/07)
  • A phase II randomized study of induction chemotherapy followed by concurrent chemo-radiotherapy in locally advanced pancreatic cancer (Chair, PI-initiated, 2013/05~)
  • A phase III, open-label, randomized study of the combination therapy with NC-6004 and gemcitabine versus gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer (Global Chair, Industry-sponsored, 2013/10~)
  • Randomized Phase II study of gemcitabine plus Z-360 in metastatic pancreatic adenocarcinoma compared with gemcitabine plus placebo (ZIPANG study) (Global Chair, Industry-sponsored, 2014/05~2014/11)
  • A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy (Co-PI, Industry-sponsored, 2014/10~)
  • Phase II trial of LDK378 as the first or second-line therapy in ROS1 and /or ALK over-expressed advanced intrahepatic or hilar cholangiocarcinoma (Chair, PI-initiated, 2015/01~)
  • A study of S-1 in combination with gemcitabine as first-line treatment in patients with advanced biliary tract cancer (Chair, Industry-sponsored, 2015/02~2016/02 )
  • Phase I Trial of ADI-PEG 20 plus cisplatin in patients with metastatic melanoma or other advanced solid malignancies (PI in Taiwan, Industry-sponsored, 2015/03~)
  • ONO-4538-12: Phase III multicenter, open-label, randomized study in patients with un-resectable advanced or recurrent gastric cancer (Steering Committee Member, Industry-sponsored, 2015/11~2016/03)
  • Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study (PI in NCKUH, Industry-sponsored, 2016/Q2~ )
  • Randomized, double-blind, phase 2 study of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine as first-line treatment in patients with advanced or metastatic biliary tract cancer (PI in NCKUH, Industry-sponsored, 2016/Q4~ )
  • A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C (M7824) in subjects with metastatic or locally advanced solid tumors with expansion to selected indications in Asia (PI in NCKUH, Industry-sponsored, 2017/Q1~ )
  • ONO-4538: Phase II multicenter, open-label, randomized study in patients with un-resectable advanced or recurrent gastric cancer (Steering Committee Member, Industry-sponsored, 2017/Q1~ )
  • Phase 2 study of biweekly gemcitabine plus S-1 and leucovorin (GSL) in elder or ECOG PS>1, advanced pancreatic cancer patients (Chair, PI-initiated, 2018/Q2~)
  • SOLAR trial: an open-label phase I/II, dose-escalation and extension cohort study of biweekly abraxane in combination with oxaliplatin and oral S-1/LV as first-line chemotherapy in patients with advanced gastric, pancreatic and biliary cancers (Chair, PI-initiated, 2018/Q2~)
  • Randomized, phase 2 study of biweekly S-1, leucovorin, oxaliplatin and gemcitabine (SLOG) vs. gemcitabine/cisplatin in advanced biliary tract cancer (Chair, PI-initiated, 2018/Q2~)
  • Randomized, phase 2 study of biweekly S-1, leucovorin, oxaliplatin and gemcitabine (SLOG) vs. modified FOLFIRINOX in advanced pancreatic cancer (Chair, PI-initiated, 2018/Q2~)
  • Phase 2 study of biweekly gemcitabine plus S-1 and leucovorin (GSL) in elder or ECOG PS>1, advanced pancreatic cancer patients (Chair, PI-initiated, 2018/Q2~)
  • Global, phase 3 study of gemcitabine vs. gemcitabine/Endo-Tag in FOLFIRINOX-failed metastatic pancreatic cancer (Global Study Chair, Industry-sponsored, 2018/Q3~)
Share Button

Comments are closed.